Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

No bones about fluoride

G R Mundy1

  • 1Department of Medicine/Endocrinology & Metabolism, University of Texas Health Science Center, San Antonio 78284, USA.

Nature Medicine
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Effective osteoporosis drugs exist, but clinical trial data indicate a need for improved treatments. Further research is essential to develop superior osteoporosis therapies.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.

Leukemia·2009
Same author

Locally delivered lovastatin nanoparticles enhance fracture healing in rats.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2007
Same author

Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2006
Same author

MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Bone·2004
Same author

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro.

The Journal of clinical investigation·2003
Same author

Osteoporosis: pathophysiology and non-pharmacological management.

Best practice & research. Clinical rheumatology·2002
Same journal

Generalizable AI predicts immunotherapy outcomes across cancers and treatments.

Nature medicine·2026
Same journal

Immune aging biomarkers for clinical trials.

Nature medicine·2026
Same journal

Lassa fever countermeasures gather pace.

Nature medicine·2026
Same journal

Why high scores do not mean application readiness for health AI.

Nature medicine·2026
Same journal

Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.

Nature medicine·2026
Same journal

Biological aging might help to explain the rising risk of early-onset cancer.

Nature medicine·2026
See all related articles

Area of Science:

  • Bone health and osteoporosis management.

Background:

  • Osteoporosis is a significant public health concern.
  • Current pharmacological interventions offer effective osteoporosis treatment.

Purpose of the Study:

  • To evaluate the efficacy of existing osteoporosis drugs.
  • To identify areas for improvement in osteoporosis pharmacotherapy.

Main Methods:

  • Analysis of clinical trial data for osteoporosis medications.
  • Comparative assessment of treatment outcomes.

Main Results:

  • Existing osteoporosis drugs demonstrate considerable effectiveness.
  • Clinical trial results reveal limitations and suggest room for enhancement.

Conclusions:

  • While current osteoporosis drugs are beneficial, the pursuit of more effective therapies remains a critical objective.
  • Future drug development should focus on addressing unmet needs in osteoporosis treatment.